Physician profile
Gerald Machen
NPI 1881676930
$1,567.02
in general payments reported to CMS, 2019-2025
31 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $191 · 2021: $370 · 2022: $313 · 2023: $185 · 2024: $102 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.78 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $193.57 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $115.68 | 2020-2021 | |
| Harmony Biosciences LLC | $84.29 | 2022 | |
| Amarin Pharma, INC. | $81.99 | 2019-2021 | |
| Pfizer INC. | $73.93 | 2021-2023 | |
| Exact Sciences Corporation | $69.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.27 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $67.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.47 | 2022-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.42 | 2019-2025 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.03 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $45.75 | 2022-2024 | Jardiance |
| Ucb, INC. | $40.44 | 2021 | |
| Dexcom, INC. | $37.79 | 2022-2023 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $31.21 | 2024-2025 | Rexulti |
| Grifols USA, LLC | $31.15 | 2020 | |
| Ironshore Pharmaceuticals INC. | $30.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.83 | 2021 | |
| Arbor Pharmaceuticals, INC. | $20.83 | 2020 | |
| Sanofi Pasteur INC. | $20.74 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.43 | 2025 | Rexulti |
| Shield Therapeutics INC | $18.70 | 2024 | |
| Corium, LLC | $17.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.27 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.94 | 2020 | |
| Glaxosmithkline, LLC. | $16.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.11 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.60 | 2025 | Adstiladrin |
| Philips North America LLC | $12.91 | 2023 | |
| Amgen INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Machen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.